TherapeuticsMD Inc (TXMD) gains 6.00% for July 21

Equities Staff  |

TherapeuticsMD Inc (NASDAQ: TXMD) shares gained 6.00%, or $0.06 per share, to close Wednesday at $1.06. After opening the day at $1.00, shares of TherapeuticsMD fluctuated between $1.06 and $1.00. 3,842,207 shares traded hands a decrease from their 30 day average of 6,157,560. Wednesday's activity brought TherapeuticsMD’s market cap to $416,781,400.

TherapeuticsMD is headquartered in Boca Raton, Florida, and employs more than 3,000 people.

About TherapeuticsMD Inc

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.

Visit TherapeuticsMD Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on TherapeuticsMD Inc and to follow the company’s latest updates, you can visit the company’s profile page here: TherapeuticsMD Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content